Asensus Surgical Inc. (ASXC) News

Asensus Surgical Inc. (ASXC): $0.75

0.05 (+7.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ASXC News Items

ASXC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ASXC News Highlights

  • For ASXC, its 30 day story count is now at 3.
  • Over the past 21 days, the trend for ASXC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ASXC News From Around the Web

Below are the latest news stories about ASENSUS SURGICAL INC that investors may wish to consider to help them evaluate ASXC as an investment opportunity.

Asensus Surgical to Host Investor Day on February 21, 2023

RESEARCH TRIANGLE PARK, N.C., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that the Company will host an Investor Day on Tuesday, February 21, 2023 in New York City. 2023 Investor Day Overview Date: Tuesday, February 21, 2023 Time: 11:30 AM EST Location: InterContinental New York Barclay Hotel A live

Yahoo | January 30, 2023

Asensus Surgical Receives CE Mark for Expanded Machine Vision Capabilities

Expanded Intelligent Surgical Unit™ (ISU™) capabilities include 3D measurement, digital tagging, image enhancement, and enhanced camera control, for our European customers The Senhance Surgical System The Senhance Surgical System is powered by the Intelligent Surgical Unit, enabling real-time surgical image analytics and machine vision-driven control of the camera. RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device compa

Yahoo | January 23, 2023

Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update. Fourth Quarter Highlights Over 690 procedures were performed globally during the quarter, representing growth of over 23% compared to the fourth quarter 2021Five Senhance® Surgical P

Yahoo | January 9, 2023

Asensus Surgical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that the management team will participate and present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 PM PST. Event: 41st Annual J.P. Morgan Healthcare Conference Date: Thursday, Janu

Yahoo | January 5, 2023

Asensus Announces Kitakyushu General Hospital in Japan to Initiate Second Senhance System

First hospital to install a second Senhance Surgical SystemRESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that Kitakyushu General Hospital (“Kitakyushu”), a hospital in the Kyushu area of Japan, entered into an agreement to lease and utilize a second Senhance® Surgical Syst

Yahoo | January 3, 2023

Asensus Announces Senhance Program Initiation at Kashiwa Kosei General Hospital of Japan

Continued expansion of the Senhance Program in the regionRESEARCH TRIANGLE PARK, N.C., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that Kashiwa Kosei General Hospital in Kashiwa, Japan has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are pleased to be partnering wit

Yahoo | December 29, 2022

Asensus Announces Senhance System Placement at GPR Klinikum Rüsselsheim of Germany

10th hospital in Germany to initiate a Senhance System The Senhance Surgical System The Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery. RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided

Yahoo | December 19, 2022

Asensus Announces Additional Senhance Surgical System Sale

Oncology focused hospital to initiate Senhance System programRESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that a Senhance® Surgical System has been sold to the Company’s distribution partner in Germany focused on Eastern Europe and the Commonwealth of Independent States (

Yahoo | December 8, 2022

Asensus Surgical to Participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference in Miami, Florida. The Company’s panel presentation, Launching on Society: Early Commercial MedTech Names with New Technologies in Large Patient Populations, will take place on Thursday, December 8,

Yahoo | November 28, 2022

Analysts Offer Insights on Services Companies: Asensus Surgical (ASXC) and Chicken Soup For The Soul Entertainment (CSSE)

There's a lot to be optimistic about in the Services sector as 2 analysts just weighed in on Asensus Surgical (ASXC – Research Report) and Chicken Soup For The Soul Entertainment (CSSE – Research Report) with bullish sentiments. Asensus Surgical (ASXC) H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Asensus Surgical today and set a price target of $3.00. The company's shares closed last Monday at $0.46, close to its 52-week low of $0.35. According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 36.9% success rate.

Catie Powers on TipRanks | November 15, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5357 seconds.